Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial

Journal of the American College of Cardiology

Volumn 34, Issue 4, 1999, Pages 966-973

  Neuhaus, Karl Ludwig ^a   Molhoek, G Peter ^b   Zeymer, Uwe ^a   Tebbe, Ulrich ^c   Wegscheider, Karl ^d   Schröder, Rolf ^d   Camez, Anne ^e   Laarman, G Jan ^f   Grollier, Gilles M ^g   Lok, Dirk J A ^h   Kuckuck, Holger ⁱ   Lazarus, Peter ^j  

^a KLINIKUM KASSEL   (Germany)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c KLINIKUM LIPPE DETMOLD   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Behringwerke AG   (Germany)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h DEVENTER HOSPITAL   (Netherlands)

ⁱ Vivantes Wenckebach Klinikum   (Germany)

^j Klinikum Schwerin   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; LEPIRUDIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY BLOOD FLOW; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; STREPTOKINASE; SURVIVAL RATE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0033213674     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00319-8     Document Type: Article

References (26)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity from all randomised trials of more than 1,000 patients . Lancet. 343:1994;311-322.
2. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival. Should the paradigm be expanded? Circulation. 79:1989;441-444.
3. Vogt A., von Essen R., Tebbe U., Feuerer W., Appel K.F., Neuhaus K.L. Impact of early perfusion status on the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction retrospective analysis of four German multicenter Studies . J Am Coll Cardiol. 21:1993;1391-1395.
4. The effects of tissue plasminogen activator, streptokinase or both on coronary patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
5. Anderson J.L., Karagounis L.A., Califf R.M. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol. 78:1996;1-8.
6. Lincoff A.M., Topol E.J. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 87:1993;1792-1805.
7. Ohman E.M., Califf R.M., Topol E.J., et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 82:1990;781-791.
8. Galvani M., Abendschein D.R., Ferrini D., Ottani F., Rusticali F., Eisenberg P.R. Failure of fixed-dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol. 24:1994;1445-1452.
9. Lefkovits J., Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 90:1994;1522-1536.
10. Neuhaus K.L., von Essen R., Tebbe U., et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III study. Circulation. 90:1994;1638-1642.
11. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndroms. Circulation. 90:1994;1631-1637.
12. Antman E.M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 90:1994;1624-1630.
13. Antman E.M. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 94:1996;911-921.
14. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
15. The Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings . N Engl J Med. 312:1985;932-936.
16. Schröder R., Dissmann R., Brüggemann T., et al. Extent of early ST segment elevation resolution a simple but strong predictor of outcome in patients with acute myocardial infarction . J Am Coll Cardiol. 24:1994;384-391.
17. Rigel D.F., Olson R.W., Lappe R.W. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombolysis. Circulation. 72:1993;1091-1102.
18. Lee L.V. Initial experience with hirudin and streptokinase in acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) 6 Trial . Am J Cardiol. 75:1995;7-13.
19. Molhoek G.P., Laarman G.J., Lok D.J.A., et al. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK). Eur Heart J. 16:(Suppl D):1995;33-37.
20. White H.D., Aylward P.E., Frey M.J., et al. A randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction. Circulation. 96:1997;2155-2161.
21. Oldgren J., Grip L., Wallentin L. Reactivation after cessation of thrombin inhibition in unstable coronary artery disease occurs regardless of aspirin dose (abstr). Circulation. 94:(Suppl I):1996;I-431.
22. Metz B.K., White H.D., Granger C.B., et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction results from the GUSTO IIb trial . J Am Coll Cardiol. 31:1998;1493-1498.
23. von Essen R., Zeymer U., Tebbe U., et al. HBW 023 (recombinant hirudin) for acceleration of thrombolysis and prevention of reocclusion in acute myocardial infarction. Results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Krankenhauskardiologen. Coron Artery Dis. 9:1998;265-272.
24. Johnson T.L., Topol E.J. Early, complete infarct vessel patency arriving at a gold standard for future clinical investigation in myocardial perfusion . J Thromb Thrombolysis. 4:1997;259-266.
25. Braunwald E., Cannon C.P., McCabe C.H. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The "unsatisfactory outcome" endpoint. Circulation. 86:1992;683-687.
26. Schröder R., Wegscheider K., Schröder K., Dissmann R., Meyer-Sabellek W. Extent of early ST segment elevation resolution a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens . J Am Coll Cardiol. 26:1995;1657-1664.